The SocietyMore than 35,000 clinicians, scientists and allied health professionals from over 160 countries are part of the ERS communityBecome an ERS member
05 Oct, 2021
Severe asthma represents a burden for both patients and society. Modulation of the underlying inflammation has been the basis of the treatment, becoming much more efficient in the biologics era, introducing precision medicine. However, representing the complexity of underlying immunopathology, we have an increasing number of immunomodulators, from inhaled corticosteroid use and allergen immunotherapy to biologics and macrolides, with many more on their way. It is becoming challenging for fellow physicians to recognise the right endotype and choose the most appropriate immunomodulatory treatment. The challenge is further increasing for fellow physicians who have difficulties referring to a specialist severe asthma clinic.
Following the webinar, participants will be able to:
Treatments that will be discussed are allergen immunotherapy, biologics, and other immune modulators as macrolides. Finally, strategies at follow up treatment and monitor its effects will be also reviewed.